- Home
- IBIO vs AARD Comparison
IBIO vs AARD Comparison
Compare IBIO & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | IBIO | AARD |
|---|---|---|
| Founded | 2008 | 2017 |
| Country | United States | United States |
| Employees | N/A | 40 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 83.5M | 85.7M |
| IPO Year | 2009 | N/A |
Fundamental Metrics
Financial Performance| Metric | IBIO | AARD |
|---|---|---|
| Price | $1.73 | $5.60 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 9 |
| Target Price | $4.75 | ★ $15.29 |
| AVG Volume (30 Days) | ★ 989.2K | 220.5K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 73.08 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.56 | $3.35 |
| 52 Week High | $3.82 | $17.94 |
Technical Indicators
Market Signals| Indicator | IBIO | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 50.90 | 64.69 |
| Support Level | $1.70 | $4.81 |
| Resistance Level | $1.80 | $6.01 |
| Average True Range (ATR) | 0.12 | 0.49 |
| MACD | 0.01 | 0.21 |
| Stochastic Oscillator | 38.89 | 81.66 |
Price Performance
Historical ComparisonAbout IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.